Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases.
TLDR
In this article, the authors describe two cases of patients with metastatic renal cell carcinoma (mRCC) whose treatment was delayed due to COVID-19 and who experienced spontaneous tumour regression following the infection.Abstract:
Spontaneous regression of metastatic renal cell carcinoma (mRCC) is a rare event, often associated with an activation of innate immunity by various triggers. SARS-CoV-2 infection induces a strong inflammatory response in some patients and a cytokine storm is one of the main causes of severe morbidity and mortality associated with the virus. Here, we describe two cases of patients with histologically and radiologically proven mRCC whose treatment was delayed due to COVID-19 and who experienced spontaneous tumour regression following the infection. Both patients reported here had predominantly pulmonary and mediastinal involvement and underwent nephrectomy. The interval between the diagnosis of COVID-19 and the detection of tumour regression was 3 and 4 months, respectively. Although approved vaccines and other measures are clearly the best way to prevent COVID-19-associated morbidity and mortality in cancer patients, we hypothesize that innate immunity activation by the infection can contribute to tumour regression in special circumstances.read more
Citations
More filters
Journal ArticleDOI
The Spontaneous Regression of Primary Gastrointestinal Malignancies: An Observational Review
Carlos D. Minacapelli,Philip Leuszkiewicz,Ankoor Patel,C. Catalano,George Abdelsayed,A T Lalos,Vinod K. Rustgi +6 more
TL;DR: In this article , an analysis of 390 cases of spontaneous regression or remission in the GI tract focuses primarily on neoplasms of the hepatobiliary system and proposes an updated version of the older inclusion criteria for spontaneous regression.
Journal ArticleDOI
Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data
TL;DR: This review provides a summary of the current state of oncology and cardiology positron emission tomography (PET) examinations related to COVID-19, and includes preparation of the nuclear medicine department, trends in PET examinations, specific imaging findings on 18F-fluorodeoxyglucose (FDG) PET/CT, and the effects of vaccines on PET imaging findings.
Journal ArticleDOI
Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment
Concetta Meo,Giuseppe De Palma,Francesca Bruzzese,Alfredo Budillon,Claudio Napoli,Filomena de Nigris +5 more
TL;DR: In this paper , the authors discuss potential mechanisms which may have contributed to the cancer regression in these cases and could be useful for future options in cancer treatment, including oncolytic and priming hypotheses.
References
More filters
Journal ArticleDOI
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Teresa Murray Law,Robert J. Motzer,Madhu Mazumdar,Kenneth W. Sell,Philip J. Walther,Michael O'Connell,Amanullah Khan M.D.,Vaia Vlamis,N. J. Vogelzang,Dean F. Bajorin +9 more
TL;DR: Treatment with interleukin‐2 (IL‐2) and lymphokine‐activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma, but the relative therapeutic benefit of the addition of LAK to IL‐2 was unknown.
Journal ArticleDOI
The Apparent Disappearance of Pulmonary Metastasis in a Case of Hypernephroma Following Nephrectomy1
Journal ArticleDOI
Antibiotics for cancer treatment: A double-edged sword.
Yuan Gao,Qingyao Shang,Wenyu Li,Wenxuan Guo,Alexander Stojadinovic,Ciaran Mannion,Ciaran Mannion,Yan-gao Man,Tingtao Chen +8 more
TL;DR: The double-edged sword of antibiotics in the field of cancer treatments is discussed, their potential mechanisms are explored and solutions to reduce the potential negative effects of antibiotics are provided.
Journal ArticleDOI
SARS-CoV-2-induced remission of Hodgkin lymphoma.
Sarah Challenor,David Tucker +1 more
Journal ArticleDOI
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.
Stanley C. Jordan,P. Zakowski,Hai P Tran,Ethan A. Smith,Cyril R. Gaultier,Gregory Marks,R. Zabner,Hayden Lowenstein,Jillian Oft,Benjamin Bluen,Catherine Le,Rita Shane,Noriko Ammerman,Ashley Vo,Peter Chen,Sanjeev Kumar,Mieko Toyoda,Shili Ge,Edmund Huang +18 more
TL;DR: Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality.